Lymphoscintigraphy in Breast Cancer
No Results
No Results
processing….
Lymphoscintigraphy (sentinel lymph node mapping) is an imaging technique that is used to identify the lymph drainage basin, determine the number of sentinel nodes, differentiate sentinel nodes from subsequent nodes, locate the sentinel node in an unexpected location, and mark the sentinel node over the skin for biopsy. Lymphoscintigraphy is indicated for proven palpable or nonpalpable invasive breast carcinoma for which removal of the primary tumor and axillary node dissection would be indicated. [1]
Sentinel node mapping is rapidly becoming an alternative staging procedure for the axilla in managing early breast cancer. [2] Several well-conducted studies have provided high-quality evidence for its usefulness. [3] Sentinel node scanning was initially studied in cutaneous melanomas to detect lymphatic drainage patterns before surgery. The procedure is applicable to almost all regions of the body, but the greatest impetus to the technique came with the application of the procedure to identify breast sentinel nodes.
The sentinel node is the first node to receive metastatic deposits in a malignancy. Lymphoscintigraphy is an important procedure because if the sentinel node is free of metastasis, subsequent nodes are also likely to be free of disease. The sentinel node is generally defined as follows:
The node closest to the primary lesion
The node with a radioactive channel leading to it
The node with the highest count rate on lymphoscintigraphic imaging and probe counting
The first node visible on lymphoscintigraphic imaging
The blue node on dye injection technique
The node with a blue channel leading to it
Lymphoscintigraphy allows the patient to avoid axillary clearance surgery (axillary lymph node dissection) if the sentinel node is negative for metastatic disease. Given the high prevalence of breast cancer worldwide, the possibility of avoiding axillary clearance surgery in a significant number of patients makes this an extremely valuable procedure.
Lymphoscintigraphy is the staging modality of choice for early breast cancer, and breast cancer trials with 5- to 10-year outcome data have shown no significant differences in disease-free survival rates or overall survival rates between lymphoscintigraphy and axial lymph node dissection but have shown significantly lower morbidity with lymphoscintigraphy. [4]
Absolute contraindications to lymphoscintigraphy include clinically positive (N1) axilla and allergy to component used. [2]
Relative contraindications to lymphoscintigraphy include the following [5] :
Prior biopsy (especially excisional biopsy)
Previous breast and axillary surgery
Advanced disease (associated with fatty degeneration of nodes with reduced function)
Neoadjuvant chemotherapy
Multicentric and multifocal disease
Ductal carcinoma in situ
High body mass index and old age
Pregnancy
Surgeon’s experience and skills
Lymphoscintigraphy has become widely accepted in several other applications besides breast cancer, [6, 7] including malignant melanoma (stage I and II disease). [8, 4, 9] Technetium-99m tilmanocept is also used for intradermal or SC injection for melanoma mapping. [10] The Multicenter Selective Lymphadenectomy Trial concluded that sentinel node scanning is a low-morbidity procedure for evaluating the regional nodal basin in early melanoma and should become the standard of care. [11] Other applications include head and neck cancer, thyroid cancer, non–small cell lung cancer, gastric cancer, [7] penile cancer, [12] and vulvar cancers. [13]
Lymphoscintigraphy equipment includes the following:
Syringes with needles of appropriate gauge, usually 25-G insulin syringes (see the image below)
Syringe shields
Tc-99m radiopharmaceutical: antimony trisulphide, particle size 0.015-0.3 µm; nanocolloid, particle size 0.05-0.8 µm; sulfur colloid, particle size 0.22 µm; or tilmanocept (Lymphoseek) [14]
Alcohol swabs and other material used during and after injections (see the image below)
Gamma camera and imaging system
Gamma-detecting probe (see the image below)
The camera should be equipped with a low-energy, high-resolution collimator and should be peaked at 140 KeV with a 20% window centered over the peak. A small magnification (1.35) is often used.
Anesthesia
No anesthesia is required.
Positioning
The patient must be imaged in the same position used for surgery, so that there is no shift when the sentinel node is marked on the skin. The patient is usually supine with the ipsilateral arm abducted at 90 degrees and suitably supported.
A false-positive result may be caused by contamination of the skin or residual activity from another nuclear medicine procedure done recently.
A false-negative result (absent or faint lymph node uptake) may be caused by a low radiopharmaceutical dose, poor radiopharmaceutical quality, insufficient radiocolloid particles, imaging time that is too early or too late, advanced patient age, or tumor replacement of nodes.
One way of reducing false-positive and false-negative results is to combine the visual assessment of nodes with intraoperative gamma counting and digital palpation through the surgical incision. [15]
Injection techniques can be divided into superficial and deep methods. The superficial techniques include intradermal, subcutaneous, subareolar, and periareolar injections. Deep techniques include peritumoral or intratumoral injections. Subcutaneous, periareolar, and subareolar techniques are associated with a low yield of nonaxillary nodes.
The combination of radiocolloid injection and blue-dye injection immediately before surgery gives the highest sensitivity and specificity of the technique. However, numerous studies have also found that SLN biopsy with radiotracer alone is successful. [16, 17] A meta-analysis found that mapping sentinel lymph node locations with methylene blue alone results in an acceptable identification rate but an excessive false-negative rate. [18]
SLN biopsy with near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) has been reported to be a highly sensitive method for SLN detection. In this method, ICG is injected and then tracked through the lymphatic ducts to SLNs using an excitation illumination system and a high-sensitivity camera. [19]
Imaging techniques must be meticulous and of a high standard. The camera should be equipped with a low-energy, high-resolution collimator and should be peaked at 140 KeV with a 20% window centered over the peak. Shielding of the injection site is usually not needed. A small magnification (1.35) is often used.
Imaging times for the various injection techniques are given in the table below.
Table. Acquisition Protocols and Imaging Times for Various Injection Types (Open Table in a new window)
Computer Matrix
Dynamic Phase
Static Phase
Intradermal
128 x 128 x 16 (dynamic) or highest available
256 x 256 x 16 (static) or highest available
20 seconds for 15-20 minutes
20 minutes, 2-3 hours, 12-24 hours (immediately prior to surgery)
Subcutaneous
256 x 256 x 16 (static) or highest available
20-30 minutes, 2 hours, 4-6 hours, prior to surgery
Peritumoral or intratumoral
256 x 256 x 16 (static) or highest available
20-30 minutes, 2 hours, 4-6 hours, prior to surgery
An anterior oblique view with a 30-degree lateral tilt is used. If a dual-head camera is used, simultaneous lateral images are also acquired.
Transmission images, radioactive markers to identify the nipple, and flexible line sources to outline the breast contour may be used to provide additional anatomical localization.
Once a sentinel node is identified, a radioactive marker is moved over skin while the patient is under the gamma camera detector, keeping the sentinel node in the field of view. With real-time imaging mode, the marker is moved until the two sources coincide (the marker and sentinel node). This area is marked with waterproof ink.
It is useful to add late images before the patient is taken for surgery to ensure that the sentinel node identified is indeed retaining the radiopharmaceutical and also to see if subsequent tier nodes have appeared.
The sentinel node is the one that appears first, is closer to the injection, and/or has a lymphatic duct connecting the injection site with the node.
Axillary nodes are seen in almost all patients, but the appearance of nodes can take several patterns, as follows:
One sentinel node, with or without a visible lymphatic duct; no second-tier nodes
One sentinel and one or more second-tier nodes
The simultaneous appearance of two nodes with same uptake intensity (twin sentinel nodes)
A node closer to the injection site that appears later than other more distant nodes (the closer node is the sentinel node)
Differentiation of the sentinel node from second-tier nodes can be made by the following:
The presence of a lymphatic channel leading to the sentinel node
The sequence of appearance (the sentinel node appears first)
The intensity of uptake (the sentinel node has more activity)
Confirmation needs blue-dye corroboration.
Intradermal Injection Technique
Many experts contend that this method offers the best results. [20] The injection is made 24 hours before the surgery, with 10-15 MBq (0.3-0.4 mCi) of the appropriate Tc-99m-labeled radiopharmaceutical used in a volume of 0.2 mL. The Tc-99m tilmanocept dose is 0.5 mCi administered at least 15 minutes before initiating intraoperative lymphatic mapping. Do not delay mapping more than 15 hours after injection of Tc-99m tilmanocept.
A 25-G needle is used, and 0.2 mL of air bubble is drawn into the syringe behind the radiopharmaceutical. The air ensures that the whole radiopharmaceutical is injected and that none of the dose is left behind in the needle; it also minimizes the risk of spillage as the syringe is withdrawn, which can lead to false-positive and false-negative results.
The injection is made in the skin overlying the tumor, and the needle is inserted at an acute angle into the skin. Proper injection technique is confirmed by the appearance of a skin bleb at the injection site. (See the image below.)
After the injection, dry cotton is applied over the injection site, and the site is sealed with an adhesive bandage. The patient is asked to massage over the injection site with dry cotton wool. This massage should continue for 1-2 minutes. (See the image below.)
Peritumoral Injection Technique
In the peritumoral injection technique, the injection is made deeper into the breast parenchyma around the mass. (See the image below.)
Usually, 4 injections are made around the tumor. The volume of injectate is larger, with 1-2 mL injected at each injection site to make a total volume of 4-8 mL. The injections are made superior, inferior, lateral, and medial to the mass. Another technique is to inject in a semicircle along the axillary side of the mass.
If the mass is nonpalpable, ultrasound guidance can be used for needle placement.
The patient is asked to massage over the injection site and between the injection site and axilla for at least 1-2 minutes. (See the image below.)
Intratumoral Injection Technique
Although some authors have advocated injection inside the tumor, there are concerns about tumor spread, especially along the needle track. Proponents claim 100% reproducibility and sentinel node visualization. [21] A small volume of radiopharmaceutical (0.2 mL), with 0.1 mL of air bubble behind it, is injected into the center of the tumor.
If the mass is nonpalpable, ultrasound guidance can be used for needle placement.
The patient is asked to massage over the injection site and between the injection site and axilla for at least 1-2 minutes.
Methylene blue, patent blue, or isosulfan blue injections are used alone or in conjunction for sentinel node identification. [22] The injection is given in the operation theater 5 minutes before the surgical incision. The injection is subdermal, peritumoral, or subareolar. (See the image below.)
A volume of approximately 1.5-2 mL is used for subdermal injections, whereas a larger volume of about 5 mL (divided into 2 aliquots) is used for peritumoral injections. The injection site is massaged as for the radiopharmaceutical injection.
A positive test is when a node is colored blue, often with a blue channel leading to it.
Note that there may be generalized blue coloration of the body, and some patients may experience allergic reaction to the dye.
Imaging the sentinel node allows the surgeon to have an idea of where to explore to retrieve the sentinel node. However, the addition of radioguidance using a gamma probe is the true strength of the technique. This also introduces a multidisciplinary element to the procedure, with breast surgeons and nuclear medicine physicians operating in close cooperation.
By using sentinel node imaging, the surgeon can determine the area where the sentinel node lies. Complete excision can be confirmed by counting the area after removing the purported sentinel node to see if the counts have fallen to background levels. The probe also guides the surgeon into the right direction and allows removal of invisible non-blue nodes that are recognizable due to their radioactive signature.
The gamma probe is covered in sterile sheath that extends to cover the connecting wire up to the display console. The display console is placed where the surgeon can easily see the display. (See the image below.)
The skin mark is confirmed to actually overlie the hottest node by placing the probe tip over the area and moving it to the surrounding areas. The hottest area is identified by the pitch of the audible signal as well as the count rate on the digital display. (See the images below.)
Background is acquired. One practice is to acquire the background over the suprasternal notch.
The line of sight [23] is established by angling the probe at the site of maximum count to determine the angle that allows the shortest distance from the skin to the sentinel node. The node is approached along the line of sight, correcting the direction with periodic input from the probe. If a blue channel is seen, this reinforces the direction.
Once the node is exposed, the probe is applied to it again to ensure that this has a high count rate (in vivo counting). If a blue dye is used and the same node is colored, this corroborates the probe data.
Once the node is removed, it is placed on the probe surface to confirm the counts (ex vivo counting). (See the image below.)
The probe is reapplied to the surgical field to confirm that the radioactive node(s) have been removed. If all radioactive nodes have been removed, the activity in the surgical bed should fall to 10% of the most active node. [23] (See the images below.)
Keshtgar M, Waddington WA, Lakhani SR, Ell PJ. Injection Techniques. The Sentinel Node in Surgical Oncology. London: Springer-Verlag; 1999. 50-59.
Krontiras H, Bland KI. When is sentinel node biopsy for breast cancer contraindicated?. Surg Oncol. 2003 Nov. 12(3):207-10. [Medline].
Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer. 2006 Jan 1. 106(1):4-16. [Medline].
Moncayo VM, Aarsvold JN, Alazraki NP. Lymphoscintigraphy and sentinel nodes. J Nucl Med. 2015 Jun. 56 (6):901-7. [Medline].
Filippakis GM, Zografos G. Contraindications of sentinel lymph node biopsy: are there any really?. World J Surg Oncol. 2007 Jan 29. 5:10. [Medline]. [Full Text].
Keshtgar M, Zaknun JJ, Sabih D, Lago G, Cox CE, Leong SP. Implementing sentinel lymph node biopsy programs in developing countries: challenges and opportunities. World J Surg. 2011 Jun. 35(6):1159-68; discussion 1155-8. [Medline].
Gipponi M, Solari N, Di Somma FC, Bertoglio S, Cafiero F. New fields of application of the sentinel lymph node biopsy in the pathologic staging of solid neoplasms: review of literature and surgical perspectives. J Surg Oncol. 2004 Mar. 85(3):171-9. [Medline].
Bluemel C, Herrmann K, Giammarile F, Nieweg OE, Dubreuil J, Testori A, et al. EANM practice guidelines for lymphoscintigraphy and sentinel lymph node biopsy in melanoma. Eur J Nucl Med Mol Imaging. 2015 Jul 25. [Medline].
Doepker MP, Zager JS. Sentinel lymph node mapping in melanoma in the twenty-first century. Surg Oncol Clin N Am. 2015 Apr. 24 (2):249-60. [Medline].
Sondak VK, King DW, Zager JS, Schneebaum S, Kim J, Leong SP, et al. Combined analysis of phase III trials evaluating [??mTc]tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma. Ann Surg Oncol. 2013 Feb. 20(2):680-8. [Medline]. [Full Text].
Morton DL, Cochran AJ, Thompson JF, Elashoff R, Essner R, Glass EC. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. 2005 Sep. 242(3):302-11; discussion 311-3. [Medline].
Horenblas S, Jansen L, Meinhardt W, Hoefnagel CA, de Jong D, Nieweg OE. Detection of occult metastasis in squamous cell carcinoma of the penis using a dynamic sentinel node procedure. J Urol. 2000 Jan. 163(1):100-4. [Medline].
Makar AP, Scheistroen M, van den Weyngaert D, Tropé CG. Surgical management of stage I and II vulvar cancer: the role of the sentinel node biopsy. Review of literature. Int J Gynecol Cancer. 2001 Jul-Aug. 11(4):255-62. [Medline].
Wallace AM, Han LK, Povoski SP, Deck K, Schneebaum S, Hall NC, et al. Comparative Evaluation of [99mTc]Tilmanocept for Sentinel Lymph Node Mapping in Breast Cancer Patients: Results of Two Phase 3 Trials. Ann Surg Oncol. 2013 Mar 17. [Medline].
Mathelin C, Croce S, Brasse D, Gairard B, Gharbi M, Andriamisandratsoa N, et al. Methylene blue dye, an accurate dye for sentinel lymph node identification in early breast cancer. Anticancer Res. 2009 Oct. 29(10):4119-25. [Medline].
He PS, Li F, Li GH, Guo C, Chen TJ. The combination of blue dye and radioisotope versus radioisotope alone during sentinel lymph node biopsy for breast cancer: a systematic review. BMC Cancer. 2016 Feb 16. 16:107. [Medline]. [Full Text].
Unkart JT, Wallace AM. Use of 99mTc-Tilmanocept as a Single Agent for Sentinel Lymph Node Identification in Breast Cancer: A Retrospective Pilot Study. J Nucl Med Technol. 2017 Sep. 45 (3):181-184. [Medline]. [Full Text].
Li J, Chen X, Qi M, Li Y. Sentinel lymph node biopsy mapped with methylene blue dye alone in patients with breast cancer: A systematic review and meta-analysis. PLoS One. 2018. 13 (9):e0204364. [Medline]. [Full Text].
Guo J, Yang H, Wang S, Cao Y, Liu M, Xie F, et al. Comparison of sentinel lymph node biopsy guided by indocyanine green, blue dye, and their combination in breast cancer patients: a prospective cohort study. World J Surg Oncol. 2017 Nov 2. 15 (1):196. [Medline]. [Full Text].
Lin KM, Patel TH, Ray A, Ota M, Jacobs L, Kuvshinoff B, et al. Intradermal radioisotope is superior to peritumoral blue dye or radioisotope in identifying breast cancer sentinel nodes. J Am Coll Surg. 2004 Oct. 199(4):561-6. [Medline].
Tanis PJ, Valdés Olmos RA, Muller SH, Nieweg OE. Lymphatic mapping in patients with breast carcinoma: reproducibility of lymphoscintigraphic results. Radiology. 2003 Aug. 228(2):546-51. [Medline].
East JM, Valentine CS, Kanchev E, Blake GO. Sentinel lymph node biopsy for breast cancer using methylene blue dye manifests a short learning curve among experienced surgeons: a prospective tabular cumulative sum (CUSUM) analysis. BMC Surg. 2009 Jan 27. 9:2. [Medline]. [Full Text].
Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol. 1993 Dec. 2(6):335-9; discussion 340. [Medline].
Computer Matrix
Dynamic Phase
Static Phase
Intradermal
128 x 128 x 16 (dynamic) or highest available
256 x 256 x 16 (static) or highest available
20 seconds for 15-20 minutes
20 minutes, 2-3 hours, 12-24 hours (immediately prior to surgery)
Subcutaneous
256 x 256 x 16 (static) or highest available
20-30 minutes, 2 hours, 4-6 hours, prior to surgery
Peritumoral or intratumoral
256 x 256 x 16 (static) or highest available
20-30 minutes, 2 hours, 4-6 hours, prior to surgery
Durre Sabih, MBBS, MSc, FRCP(Edin) Director, Multan Institute of Nuclear Medicine and Radiotherapy (MINAR), Nishtar Hospital, Pakistan
Disclosure: Nothing to disclose.
Ali Nawaz Khan, MBBS, FRCS, FRCP, FRCR Consultant Radiologist and Honorary Professor, North Manchester General Hospital Pennine Acute NHS Trust, UK
Ali Nawaz Khan, MBBS, FRCS, FRCP, FRCR is a member of the following medical societies: American Association for the Advancement of Science, American Institute of Ultrasound in Medicine, British Medical Association, Royal College of Physicians and Surgeons of the United States, British Society of Interventional Radiology, Royal College of Physicians, Royal College of Radiologists, Royal College of Surgeons of England
Disclosure: Nothing to disclose.
Mahan Mathur, MD Assistant Professor of Radiology and Biomedical Imaging, Yale University School of Medicine; Director, Medical Student Education, Associate Director, Diagnostic Radiology Residency Program, Yale-New Haven Hospital
Mahan Mathur, MD is a member of the following medical societies: American College of Radiology, American Roentgen Ray Society, Radiological Society of North America
Disclosure: Nothing to disclose.
Gowthaman Gunabushanam, MD, FRCR Assistant Professor, Department of Diagnostic Radiology, Yale University School of Medicine
Gowthaman Gunabushanam, MD, FRCR is a member of the following medical societies: American Roentgen Ray Society, Connecticut State Medical Society
Disclosure: Nothing to disclose.
Lymphoscintigraphy in Breast Cancer
Research & References of Lymphoscintigraphy in Breast Cancer |A&C Accounting And Tax Services
Source
0 Comments